2022-09-12| Trials & Approvals

BMS’s Once-Daily Plaque Psoriasis Treatment, Sotyktu, Gains FDA Approval to Rival Otezla

by Reed Slater
Share To
With solid data from two sets of clinical trials, the FDA approved Bristol Myers Squibb’s Sotyktu as a once-daily oral medication to treat moderate to severe plaque psoriasis. A day after the approval announcement, BMS posted more data supporting the drug’s promise from a long-term clinical trial demonstrating Sotyktu’s efficacy for up to two years with continuous treatment for plaque psoriasis. 
Potential New Standard for Orally Administered Plaque Psoriasis Treatment

Plaque psoriasis is a prevalent, immune-mediated condition characterized by raised, inflamed, and scaly patches of skin covered with a silvery-white buildup of dead skin that may be painful or itchy for the patient. Approximately 7.5 million Americans have psoriasis, and about 90% of those suffer from plaque psoriasis. Nearly a quarter of Americans with plaque psoriasis deal with moderate to severe manifestations of the condition.

It's free! Log in now to read

From Sweet to Risky: The Alarming Findings on Sucralose’s Genotoxicity
GHG Emissions as a ESG Metric
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
Krystal Biotech’s First Topical Gene Therapy Approved by FDA
The Emergence of General AI for Medicine: Medical Applications of ChatGPT
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
Scroll to Top